Oxynormoro

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxynormoro (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxynormoro, is an opioid analgesic presented as a strength/form for oral use. It treats moderate to severe pain in adult patients when other analgesics are insufficient.

GNH India supplies Oxynormoro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mundipharma Sas

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxynormoro is an opioid analgesic that acts on the central nervous system to manage pain across several clinical contexts.

Acute postoperative pain: Provides rapid relief of pain following surgical procedures.
Cancer‑related pain: Helps control persistent pain associated with malignant disease.
Chronic non‑cancer pain: Used when long‑term pain requires strong opioid therapy.
Severe traumatic injury pain: Alleviates intense pain from major injuries.
Palliative care pain: Improves comfort in end‑of‑life settings.

How It Works

Oxycodone Hydrochloride binds to μ‑opioid receptors in the central nervous system, activating inhibitory G‑protein pathways that reduce neuronal excitability and diminish the perception of pain. This receptor activation also modulates neurotransmitter release, contributing to its analgesic effect.

Side Effects

Side effects vary in frequency and severity and should be monitored during therapy.

Common Side Effects

Constipation: Reduced gastrointestinal motility leading to hard stools.
Nausea: Feeling of queasiness, often accompanied by vomiting.
Drowsiness: Generalized sedation and reduced alertness.
Dry mouth: Decreased salivary flow causing oral discomfort.
Dizziness: Light‑headed sensation, especially when standing quickly.
Itching: Mild pruritus without rash.

Serious or Rare Side Effects

Respiratory depression: Marked slowing of breathing that can be life‑threatening.
Severe hypotension: Dangerous drop in blood pressure.
Opioid use disorder: Development of dependence or addiction.
Seizures: Uncommon but possible convulsive events.
Anaphylaxis: Rare severe allergic reaction with airway compromise.
adrenal insufficiency: Uncommon hormonal imbalance affecting stress response.

Precautions & Warnings

When prescribing Oxynormoro, clinicians should consider several safety measures to minimize risk.

Assess pain severity: Confirm that opioid therapy is appropriate for the patient’s level of pain.
Evaluate medical history: Review for respiratory disorders, liver or kidney impairment, and substance‑use history.
Monitor for sedation: Observe patients for excessive drowsiness or impaired cognition.
Avoid concurrent CNS depressants: Limit use of alcohol, benzodiazepines, or other sedatives.
Educate on dependence risk: Inform patients about signs of tolerance and addiction.
Store at below 25°C: Keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxynormoro can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: Combined use can cause profound respiratory depression and excessive sedation.
CNS depressants: Alcohol, barbiturates, or other sedatives increase risk of life‑threatening respiratory depression.
MAO‑inhibitors: May precipitate hypertensive crisis or severe serotonin syndrome.

Moderate Interactions (Monitor Closely)

Anticholinergics: May worsen constipation, a common opioid side effect.
CYP3A4 inhibitors: Drugs like ketoconazole can raise oxy‑blood levels, enhancing toxicity.
CYP3A4 inducers: Rifampicin may lower oxycodone concentrations, reducing analgesic effect.

Frequently Asked Questions

Oxynormoro contains oxycodone hydrochloride, an opioid analgesic prescribed for moderate to severe pain when other treatments are insufficient. It is commonly used after surgery, in cancer‑related pain, and for severe traumatic injuries, providing strong pain relief under medical supervision.

Oxycodone hydrochloride binds to μ‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that lower neuronal firing and reduce the transmission of pain signals. This receptor activation also influences neurotransmitter release, producing its analgesic effect.

The appropriate dose of Oxynormoro is determined by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, renal and hepatic function, and other individual factors. Dosing regimens are individualized and should follow local prescribing guidelines.

Oxycodone crosses the placenta and is excreted in breast milk, potentially affecting the fetus or infant. Use during pregnancy or lactation is only considered when the benefit outweighs the risk, and it should be prescribed by a specialist familiar with maternal‑fetal medicine.

To request Oxynormoro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oxynormoro (oxycodone) offers potent analgesia comparable to morphine but with a higher oral bioavailability, allowing effective pain control with fewer doses. Its pharmacokinetic profile differs from hydromorphone or fentanyl, influencing onset, duration and side‑effect patterns, which clinicians consider when selecting therapy.

Oxynormoro should be stored at temperatures below 25 °C, in its original packaging to protect from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged.

Oxynormoro is supplied as an oral formulation intended for swallowing whole with water. It may be taken with or without food, but consistent administration with respect to meals helps maintain stable drug levels.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or addiction, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of these events, especially during dose initiation or escalation.

Oxynormoro is contraindicated in individuals with known hypersensitivity to oxycodone or other opioids, those with severe respiratory depression, acute or severe asthma, and patients who have taken monoamine oxidase inhibitors within the past 14 days. Caution is also advised for patients with uncontrolled substance‑use disorder.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 11 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.